Pre-made Mosunetuzumab benchmark antibody ( Bispecific mAb, anti-CD3E;MS4A1/CD20 therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-356

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-356 Category Tags ,

Product Details

Pre-Made Mosunetuzumab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells.

Products Name (INN Index)

Pre-Made Mosunetuzumab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody

INN Name

Mosunetuzumab

Target

CD3E,MS4A1

Format

Bispecific mAb

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa,Kappa

Highest_Clin_Trial (Jan '20)

Phase-III

Est. Status

Active

100% SI Structure

None;None

99% SI Structure

None;None

95-98% SI Structure

None;4k7p:YX

Year Proposed

2017

Companies

Genentech

Conditions Approved

NA

Conditions Active

Diffuse large B cell lymphoma,Chronic lymphocytic leukaemia,Non-Hodgkin's lymphoma,Follicular lymphoma

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

CD3E,MS4A1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide